138 related articles for article (PubMed ID: 35844989)
1. Genomic profiling of CD20 negative diffuse large B cell lymphoma identifies targetable mutations: A case report.
Maqbool MG; Lim JH; Jain S; Talaulikar D
EJHaem; 2020 Nov; 1(2):593-595. PubMed ID: 35844989
[No Abstract] [Full Text] [Related]
2. Primary central nervous system CD20-negative diffuse large B-cell lymphoma: a case report.
Luo S; Huang X; Li Y; Wang J
BMC Neurol; 2022 Dec; 22(1):504. PubMed ID: 36581860
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.
Cani AK; Soliman M; Hovelson DH; Liu CJ; McDaniel AS; Haller MJ; Bratley JV; Rahrig SE; Li Q; Briceño CA; Tomlins SA; Rao RC
Mod Pathol; 2016 Jul; 29(7):685-97. PubMed ID: 27102345
[TBL] [Abstract][Full Text] [Related]
4. De Novo Unclassifiable CD20-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic and Therapeutic Challenge.
AbdullGaffar B; Seliem RM
Int J Surg Pathol; 2018 May; 26(3):266-270. PubMed ID: 28982264
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus-Positive CD20- and CD45-Negative Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.
Starr A; Kwon DH; Kallakury B
Int J Surg Pathol; 2019 Feb; 27(1):98-101. PubMed ID: 29968492
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. [CD20-negative diffuse large B-cell lymphoma complicated by rheumatoid arthritis].
Yoshino T; Makiyama J; Imaizumi Y; Matsuo E; Kitanosono H; Nakashima J; Kato T; Miyoshi H; Ohshima K; Yoshida S; Miyazaki Y
Rinsho Ketsueki; 2020; 61(1):33-38. PubMed ID: 32023600
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.
Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C
Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036
[TBL] [Abstract][Full Text] [Related]
9. Unclassifiable CD20-negative Testicular Diffuse Large B-cell Lymphoma.
Garrido-Abad P; García-Martín L; Villar-Zarra K; Díaz-Menéndez A; Fernández-Arjona M
Urology; 2018 Jul; 117():e3-e4. PubMed ID: 29723590
[TBL] [Abstract][Full Text] [Related]
10. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
11. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Duman BB; Sahin B; Ergin M; Guvenc B
Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
[TBL] [Abstract][Full Text] [Related]
12. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
13. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.
Castillo JJ; Chavez JC; Hernandez-Ilizaliturri FJ; Montes-Moreno S
Expert Rev Hematol; 2015 Jun; 8(3):343-54. PubMed ID: 25641215
[TBL] [Abstract][Full Text] [Related]
14. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
15. CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma.
Nakamaki T; Fukuchi K; Nakashima H; Ariizumi H; Maeda T; Saito B; Yanagisawa K; Tomoyasu S; Homma M; Shiozawa E; Yamochi-Onizuka T; Ota H
Eur J Haematol; 2012 Oct; 89(4):350-5. PubMed ID: 22805426
[TBL] [Abstract][Full Text] [Related]
16. Primary breast CD20-positive extranodal NK/T cell lymphoma with stomach involvement: a case report and literature review.
Zhang Y; Wang K; Tan Q; Yang K; Wu D; Xu Y; Zhao X; Jiang Z
Diagn Pathol; 2021 Nov; 16(1):103. PubMed ID: 34749754
[TBL] [Abstract][Full Text] [Related]
17. De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.
Tokunaga T; Tomita A; Sugimoto K; Shimada K; Iriyama C; Hirose T; Shirahata-Adachi M; Suzuki Y; Mizuno H; Kiyoi H; Asano N; Nakamura S; Kinoshita T; Naoe T
Cancer Sci; 2014 Jan; 105(1):35-43. PubMed ID: 24147568
[TBL] [Abstract][Full Text] [Related]
18. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.
Johnson NA; Leach S; Woolcock B; deLeeuw RJ; Bashashati A; Sehn LH; Connors JM; Chhanabhai M; Brooks-Wilson A; Gascoyne RD
Haematologica; 2009 Mar; 94(3):423-7. PubMed ID: 19211644
[TBL] [Abstract][Full Text] [Related]
19. Development of combinatorial antibody therapies for diffuse large B cell lymphoma.
Geanes ES; Krepel SA; McLennan R; Pierce S; Khanal S; Bradley T
Front Med (Lausanne); 2022; 9():1034594. PubMed ID: 36353222
[TBL] [Abstract][Full Text] [Related]
20. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
Li YJ; Li ZM; Rao HL; Xia Y; Huang HQ; Xia ZJ; Li S; Li WY; Jiang WQ
J Transl Med; 2012 May; 10():84. PubMed ID: 22554077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
